Volume 8, Issue 2, Pages 5-8
Background: Delayed diagnosis and treatment done on its basis has been proven to be a factor causing increase in rate of MDR TB. So we used GenoType MTBDR plus assay® in order to determine rate of MDR-TB, Isoniazid and Rifampicin mono resistance and common mutation pattern associated with them from our area in order to provide better patient care and reduce rate of MDR-TB. Subjects and Methods: This was a cross sectional prospective study comprising of 150 smear positive sputum samples collected during period of 11⁄2 years from January 2018 to April 2019. Results: Out of total 150 smear positive samples 97 were from male patients and 53 from female patients. Rate of MDR TB found was 18/150 (12%), rifampicin mono resistance and isoniazid mono resistance was 10/150 (6.6%) and 13/150 (8.6%) respectively. Highest percentage of MDR TB was seen among defaulter cases (27.3%) followed by failure cases (25%) and relapse cases (12.5%). Mutation pattern most commonly reported for rifampicin is S531L in rpoB gene at codon 530-533 and for isoniazid was S315T1 in katG gene at codon 315. Conclusion: Problem of MDR-TB is continuously rising, so rapid detection of TB along with drug sensitivity is the need of hour and should be given utmost priority for END TB strategy. The GenoType MTBDR plus (LPAs) assay approved by world health organization is highly specific (≥99%) and sensitive (≥97%) diagnostic test for the detection of first line drugs resistance and is a rapid and reliable diagnostic tool.
MDR-TB, LPA, rpo B, katG gene.
Received 01 June 2019
Accepted 01 June 2019
It is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits authors to retain ownership of the copyright for their content, and allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. https://creativecommons.org/licenses/by/4.0/
Asian Journal of Medical Research (AJMR) is an international, peer-reviewed, quarterly open-access journal publishing advanced research across medical specialties.